위암환자에서 EAP 화학요법으로 유발된 백혈구 감소증에 대한 Neutrogin(rhG-CSF)의 임상효과

Abstract

Clinical effects of Gracin (rhG-CSF) were investigated in 24 patients receiving chemotherapy for stomach cancer (adenocarcinoma). Each patients was treated with two cycles of EAP chemotherapy. In the first cycle of chemotherapy patients received chemotherapy alone, while in the second cycles rhG-CSF was given subcutaneous for 14 days at a dove of 75㎍/day. No significant difference of the nadir counts of leukocyte and leukocyte and neutrophil were observed. The recovery time required for leukocytes to reach more than 4,000/㎣ and for neutrophil to reach more than 2,000/㎣ after the nadir was significantly reduced in the second cycle compared with the first cycle. The time needed for recovery of the leukocyte counts to reach 4,000/mm4 or more and of the neutrophil count to reach 2,000/㎣ or more after start of each chemotherapy cycle was also significantly reduced in the second cycles than first cycle. In the first cycle, febrile episodes were experienced in five patients (21%) and in the second cycle, in six patients (25%). Bone pain (4.2%), elevation of GOT, GPT, ALP (4.2%). G-I trouble (12.5%) were obserbed as side effects of rhG-CSF. In the over all evaluation, the effectiveness and usefulness of rhG-CSF was 83.3% and 70.8%, respectively. There result demonstrat8ing that Gracin (rhG-CSF) significantly shortened the duration of neutropenia and recovery time from neutropenia. Gracin (rhG-CSF) is effective and useful for the treatment of neutropenia induced by anticancer chemotherapy.